Advertisement

Sporadic Pancreatic Endocrine Tumors

  • Volker Fendrich
  • Peter Langer
  • Detlef K. Bartsch
Reference work entry

Abstract:

Pancreatic endocrine tumors (PETs) are uncommon but fascinating tumors with an annual incidence of 1 per 100,000 people. PETs present as either functional tumors, causing specific hormonal syndromes like Zollinger-Ellison-Syndrome (ZES) or organic hyperinsulinism, or as non-functional pancreatic tumors (NFPTs). The natural history of PETs is highly variable. Small, benign neoplasms such as 90% of all insulinomas are readily curable by surgical resection. Most other functional and malignant NFPTs have a less favorable chance for cure. Patients with completely resected tumors generally have a good prognosis, and an aggressive surgical approach combined with conservative treatment options in patients with advanced disease often results in long-term survival.

Keywords

Liver Metastasis Orthotopic Liver Transplantation Islet Cell Tumor Duodenal Tumor Duodenal Gastrinomas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Öberg K, Eriksson B: Endocrine tumors of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753–781.PubMedCrossRefGoogle Scholar
  2. 2.
    Rindi G, Candusso ME Solcia E: Molecular aspects of the endocrine tumours of the pancreas and the gastrointestinal tract. Ital J Gastroenterol Hepatol 1999;31(Suppl. 2):S135–S138.PubMedGoogle Scholar
  3. 3.
    Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A: Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001;84:253–262.PubMedCrossRefGoogle Scholar
  4. 4.
    Speel EJ, Richter J, Moch H, et al.: Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999;155:1787–1794.PubMedGoogle Scholar
  5. 5.
    Stumpf E, Aalto Y, Hoog A, Kjellman M, Otonkoski T, Knuutila S, et al.: Chromosomal alterations in human pancreatic endocrine tumors. Genes Chromosomes Cancer 2000;29:83–87.PubMedCrossRefGoogle Scholar
  6. 6.
    Terris B, Meddeb M, Marchio A, Danglot G, Flejou JF, Belghiti J, et al.: Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998;22:50–56.PubMedCrossRefGoogle Scholar
  7. 7.
    Kytola S, Hoog A, Nord B, Cedermark B, Frisk T, Larsson C, et al.: Comparative genomic hybridization identifies loss of 18q22—qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001;158:1803–1808.PubMedGoogle Scholar
  8. 8.
    Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, et al.: Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 2001;48:536–541.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao J, Moch H, Scheidweiler AF, et al.: Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 2001;32:364–372.PubMedCrossRefGoogle Scholar
  10. 10.
    Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM: The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292–2309.PubMedCrossRefGoogle Scholar
  11. 11.
    Rigaud G, Missiaglia E, Moore PS, et al.: High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285–292.PubMedGoogle Scholar
  12. 12.
    Debelenko LV, Zhuang Z, Emmert-Buck MR, et al.: Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997;57:2238–2243.PubMedGoogle Scholar
  13. 13.
    Chung DC, Smith AP, Louis DN, et al.: A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest 1997;100:404–410.PubMedCrossRefGoogle Scholar
  14. 14.
    Heitz PU, Kasper M, Polak JM, Kloppel G: Pancreatic endocrine tumors. Hum Pathol 1982;13:263–271.PubMedCrossRefGoogle Scholar
  15. 15.
    Bajetta E, Ferrari L, Martinetti A, et al.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858–865.PubMedCrossRefGoogle Scholar
  16. 16.
    Panzuto F, Severi C, Cannizzaro R, et al.: Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004;27:6–11.PubMedGoogle Scholar
  17. 17.
    Mansour JC, Chen H: Pancreatic endocrine tumors. J Surg Res 2004;120:139–161.PubMedCrossRefGoogle Scholar
  18. 18.
    Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006;244:845–851; discussion 852–853.PubMedCrossRefGoogle Scholar
  19. 19.
    Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633–2642.PubMedCrossRefGoogle Scholar
  20. 20.
    Service FJ, McMahon MM, O’Brien PC, Ballard DJ: Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711–719.PubMedGoogle Scholar
  21. 21.
    Burns AR, Dackiw APB: Insulinoma. Curr treat Options Oncol 2003;4:309–317.PubMedCrossRefGoogle Scholar
  22. 22.
    Service FJ: Hypoglycemic disorders. New Engl J Med 1995;332:1144–1152.PubMedCrossRefGoogle Scholar
  23. 23.
    Whipple AO: Adenomas of the islet cells with hyperinsulinism. Ann Surg 1935;101:1299.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaczirek K, Niederle B: Nesidioblastosis: an old term and a new understanding. World J Surg 2004;28:1227–1230.PubMedCrossRefGoogle Scholar
  25. 25.
    Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M: Diagnosis and therapy in 40 patients with insulinoma. Dtsch Med Wochenschr 2004;129:941–946.PubMedCrossRefGoogle Scholar
  26. 26.
    van Heerden JA, Edis AJ: Insulinoma: diagnosis and management. Surg Rounds 1980;42–51.Google Scholar
  27. 27.
    Rothmund M, Angelini L, Brunt M, et al.: Surgery for benign insulinoma: an international review. World J Surg 1990;14:393–398.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Heerden JA, Grant CS, Czako PF, Service FJ, Charboneau JW: Occult functioning insulinomas: Which localizing studies are indicated? Surgery 1992;112:1010–1014.PubMedGoogle Scholar
  29. 29.
    Rösch T, Lightdale CJ, Botet JF, et al.: Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Eng J Med 1992;326:1721.CrossRefGoogle Scholar
  30. 30.
    Palazzo L, Roseau G, Chaussade S, et al.: Pancreatic endocrine tumors: contribution of ultrasound endoscopy in the diagnosis of localization. Ann Chir 1993;47:419.PubMedGoogle Scholar
  31. 31.
    Anderson MA, Carpenter S, Thompson NW, et al.: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271.PubMedCrossRefGoogle Scholar
  32. 32.
    Kann P, Bittinger F, Engelbach M, et al.: Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy. Eur J Med Res 2001;6:385.PubMedGoogle Scholar
  33. 33.
    Bottger TC, Weber W, Beyer J, Junginger T: Value of tumor localization in patients with insulinomas. World J Surg 1990;14:07.CrossRefGoogle Scholar
  34. 34.
    Hashimoto LA, Walsh RM: Preoperative localization of insulinomas is not necessary. Am Coll Surg 1999;189:368.CrossRefGoogle Scholar
  35. 35.
    King CM, Reznek RH, Dacie JE, et al.: Imaging islet cell tumours. Clin Radiol 1994;49:295–303.PubMedCrossRefGoogle Scholar
  36. 36.
    Power N, Reznek RH: Imaging pancreatic islet cell tumours. Imaging 2002;14:147–159.Google Scholar
  37. 37.
    Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005;19:195–211.PubMedCrossRefGoogle Scholar
  38. 38.
    Van Hoe L, Gryspeerdt S, Marchal G, et al.: Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. ARJ Am J Roentgenol 1995;165:1437–1439.Google Scholar
  39. 39.
    Debray MP, Geoffroy O, Laissy JP, et al.: Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001;74:1065–1070.PubMedGoogle Scholar
  40. 40.
    de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP: Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28 (11 Suppl International):132–136.PubMedGoogle Scholar
  41. 41.
    Won JG, Tseng HS, Yang AH, Tang KT, Jap TS, Kwok CF, Lee CH, Lin HD: Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism. 2003;52:1320–1329.PubMedCrossRefGoogle Scholar
  42. 42.
    Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA: Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg. 2001;136:1020–1025.PubMedCrossRefGoogle Scholar
  43. 43.
    Doppmann JL, Miller DL, Chang R, et al.: Insulinomas: Localization with selective intraarterial injection of calcium. Radiology 1991;178:237.Google Scholar
  44. 44.
    Fernandez-Cruz L, Cesar-Borges G: Laparoscopic strategies for resection of insulinomas. J Gastrointest Surg 2006;10:752–760.PubMedCrossRefGoogle Scholar
  45. 45.
    Fendrich V, Langer P: Minimally invasive surgery for pancreatic endocrine tumours. Br J Surg 2007;94:1187–1188.PubMedCrossRefGoogle Scholar
  46. 46.
    Hirshberg B, Libutti SK, Alexander HR, et al.: Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg 2002;194:761–764.PubMedCrossRefGoogle Scholar
  47. 47.
    Langer P, Bartsch DK, Fendrich V, Kann PH, Rothmund M, Zielke A: Minimal-invasive operative treatment of organic hyperinsulinism. Dtsch Med Wochenschr 2005;130:508–513.PubMedCrossRefGoogle Scholar
  48. 48.
    Carrere N, Abid S, Julio CH, Bloom E, Pradere B: Spleen-preserving distal pancreatectomy with excision of splenic artery and vein: a case-matched comparison with conventional distal pancreatectomy with splenectomy. World J Surg. 2007;31:375–382.PubMedCrossRefGoogle Scholar
  49. 49.
    Assalia A, Gagner M: Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004;28:1239–1247.PubMedCrossRefGoogle Scholar
  50. 50.
    Ayav A, Bresler L, Brunaud L, Boissel P; SFCL (Societe Francaise de Chirurgie Laparoscopique); AFCE (Association Francophone de Chirurgie Endocrinienne): Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg. 2005;390:134–140.PubMedCrossRefGoogle Scholar
  51. 51.
    Fernandez-Cruz L, Martinez I, Cesar-Borges G, Astudillo E, Orduna D, Halperin I, Sesmilo G, Puig M: Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1. J Gastrointest Surg. 2005;9:381–388.PubMedCrossRefGoogle Scholar
  52. 52.
    Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, Fabre JM, Boulez J, Baulieux J, Peix JL, Gigot JF; Hepatobiliary and Pancreatic Section (HBPS) of the Royal Belgian Society of Surgery; Belgian Group for Endoscopic Surgery (BGES): Club Coelio. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 2005;137:597–605.PubMedCrossRefGoogle Scholar
  53. 53.
    Lo CY, van Heerden JA, Thompson GB, Grant CS, Soreide JA, Harmsen WS: Islet cell carcinoma of the pancreas. World J Surg 1996;20:878.PubMedCrossRefGoogle Scholar
  54. 54.
    Zollinger RM, Ellison EH: Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709–723.PubMedCrossRefGoogle Scholar
  55. 55.
    Roy P, Venzon DJ, Shojamanesh H, et al.: Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000;79:379–411.PubMedCrossRefGoogle Scholar
  56. 56.
    Stabile BE, Morrow DJ, Passaro E : The gastrinoma triangle: Operative implications. Am J Surg 1987;209:550.Google Scholar
  57. 57.
    Zogakis TG, Gibril F, Libutti SK, et al.: Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg 2003;238:42–48.PubMedCrossRefGoogle Scholar
  58. 58.
    Jensen RT, Gardner JD: Gastrinoma. In: The Pancreas: Biology, Pathobiology and Disease, 2nd ed. Go VLW, Di Magno EP, Gardner JD (eds.). New York, Raven Press, 1993, pp. 931.Google Scholar
  59. 59.
    Hoffmann KM, Furukawa M, Jensen RT: Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005;19:675–697.PubMedCrossRefGoogle Scholar
  60. 60.
    Sugg SL, Norton JA, Fraker DL, et al.: A prospective study of intraoperative methods to find and resect duodenal gastrinomas. Ann Surg 1993;218:138.PubMedCrossRefGoogle Scholar
  61. 61.
    Norton JA, Fraker DL, Alexander HR, et al.: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635.PubMedCrossRefGoogle Scholar
  62. 62.
    Zimmer T, Scherübl H, Faiss S, et al.: Endoscopic ultrasonography of neuroendocrine tumors. Digestion 2000;62(Suppl1):45.PubMedCrossRefGoogle Scholar
  63. 63.
    Gibril F, Reynolds JC, Doppmann JL, et al.: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26.PubMedGoogle Scholar
  64. 64.
    Imamura M, Takahashi K, Isobe Y, et al.: Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg 1989;210:710.PubMedCrossRefGoogle Scholar
  65. 65.
    Norton JA, Alexander HR, Fraker DL, et al.: Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004;239:617.PubMedCrossRefGoogle Scholar
  66. 66.
    Ellison EC, Sparks J, Verducci JS, Johnson JA, Muscarella P, Bloomston M, Melvin WS: 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg 2006;202:897–905.PubMedCrossRefGoogle Scholar
  67. 67.
    Thodiyil PA, El-Masry NS, Williamson RC: Achieving eugastrinaemia in Zollinger-Ellison syndrome: resection or enucleation? Dig Surg 2001;18:118–123.PubMedCrossRefGoogle Scholar
  68. 68.
    Stadil F, Bardram L, Gustafsen J, Efsen F: Surgical treatment of the Zollinger-Ellison syndrome. World J Surg 1993;17:463–467.PubMedCrossRefGoogle Scholar
  69. 69.
    Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M: Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005 Dec; 242:757–764, discussion 764–766.PubMedCrossRefGoogle Scholar
  70. 70.
    Tonelli F, Fratini G, Nesi G, et al.: Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006;244:61–70.PubMedCrossRefGoogle Scholar
  71. 71.
    Melvin WS, Johnson JA, Sparks J, Innes JT, Ellison EC: Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 1993;114:1183–1188.PubMedGoogle Scholar
  72. 72.
    Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, et al.: Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244:410–419.PubMedGoogle Scholar
  73. 73.
    Jaskowiak NT, Fraker DL, Alexander HR, et al.: Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome? Surgery 1996;120:1055–1063.PubMedCrossRefGoogle Scholar
  74. 74.
    Weber HC, Venzon DJ, Fishbein VA, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637–1649.PubMedCrossRefGoogle Scholar
  75. 75.
    Yu F, Venzon DJ, Serrano J, et al.: Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999;17:615–630.PubMedGoogle Scholar
  76. 76.
    de Herder WW, Lamberts SW: Clinical endocrinology and metabolism. Gut endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2004;18:477–495.PubMedCrossRefGoogle Scholar
  77. 77.
    Perry RR, Vinik AI: Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995;80:2273–2278.PubMedCrossRefGoogle Scholar
  78. 78.
    Soga J, Yakuwa Y: Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998;17:389–400.PubMedGoogle Scholar
  79. 79.
    Chastain MA: The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001;321:306–320.PubMedCrossRefGoogle Scholar
  80. 80.
    Krejs GJ, Orci L, Conlon JM, et al.: Somatostatinoma syndrome. N Engl J Med 1979;301:285.PubMedCrossRefGoogle Scholar
  81. 81.
    Mao C, Shah A, Hanson D, Howard J: Von Recklinghausen’s Disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995;59:67.PubMedCrossRefGoogle Scholar
  82. 82.
    O’Brien TD, Chejfec G, Prinz RA: Clinical features of duodenal somatostatinomas. Surgery 1993;114:1144.PubMedGoogle Scholar
  83. 83.
    Soga J, Yakuwa Y: Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999;18:13–22.PubMedGoogle Scholar
  84. 84.
    Grant CS: Surgical management of malignant islet cell tumors. World J Surg 1993;17:498–503.PubMedCrossRefGoogle Scholar
  85. 85.
    Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB: Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 2005;89:170–185.PubMedCrossRefGoogle Scholar
  86. 86.
    Bartsch DK, Schilling T, Ramaswamy A, et al.: Management of non-functioning islet cell carcinomas. World J Surg 2000;24:1418.PubMedCrossRefGoogle Scholar
  87. 87.
    Sarmiento JM, Farnell MB, Que FG, et al.: Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis. World J. Surg. 2002;26:1267–1271.PubMedCrossRefGoogle Scholar
  88. 88.
    Evans DB, Skibber JM, Lee JE, et al.: Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993;114:1175–1182.PubMedGoogle Scholar
  89. 89.
    Solorzano CC, Lee JE, Pisters PWT, et al.: Nonfunctioning islet all carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078–1085.PubMedCrossRefGoogle Scholar
  90. 90.
    Kent RB, van Heerden JA, Weiland LH, et al.: Nonfunctioning islet cell tumors. Ann Surg 1981;193:185–190.PubMedCrossRefGoogle Scholar
  91. 91.
    Broughan TA, Leslie JD, Soto JM, et al.: Pancreatic islet cell tumors. Surgery 1986;99:671–678.PubMedGoogle Scholar
  92. 92.
    Thompson GB, van Heerden JA, Grant CS, et al.: Islet cell carcinoma of the pancreas: a twenty-year experience. Surgery 1988;104:1011–1017.PubMedGoogle Scholar
  93. 93.
    Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al.: Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241:776–785.PubMedCrossRefGoogle Scholar
  94. 94.
    Dousset B, Saint-Marc O, Pitre J, et al.: Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908–914.PubMedCrossRefGoogle Scholar
  95. 95.
    Que FG, Nagorny DM, Batts KP, et al.: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36–42.PubMedCrossRefGoogle Scholar
  96. 96.
    Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88–192.PubMedCrossRefGoogle Scholar
  97. 97.
    Chamberlain RS, Canes D, Brown KT, et al.: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–435.PubMedCrossRefGoogle Scholar
  98. 98.
    Nave H, Mossinger E, Feist H, et al.: Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001;129:170–175.PubMedCrossRefGoogle Scholar
  99. 99.
    Sarmiento JM, Heywood G, Rubin J, et al.: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29–37.PubMedCrossRefGoogle Scholar
  100. 100.
    Pascher A, Klupp J, Neuhaus P: Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:637–648.PubMedCrossRefGoogle Scholar
  101. 101.
    Rosenau J, Bahr MJ, von Wasielewski R, et al.: Ki67, E-cadherin, and p53 as prognostic indicators of longterm outcome after liver transplantation for metastatic neuroendocrine tumours. Transplantation 2002;73:386–394.PubMedCrossRefGoogle Scholar
  102. 102.
    Olausson M, Friman S, Cahlin C, et al.: Indications and results of liver transplantation in patients with neuroendocrine tumours. World J Surg 2002;26:998–1004.PubMedCrossRefGoogle Scholar
  103. 103.
    Le Treut YP, Delpero JR, Dousset B, et al.: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997;225:355–364.PubMedCrossRefGoogle Scholar
  104. 104.
    Hellman P, Ladjevardi S, Skogseid B et al.: Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002;26:1052–1056.PubMedCrossRefGoogle Scholar
  105. 105.
    O’Toole D, Ruszniewski P: Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585–594.PubMedCrossRefGoogle Scholar
  106. 106.
    Toumpanakis C, Meyer T, Caplin ME : Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:131–144.PubMedCrossRefGoogle Scholar
  107. 107.
    Forrer F, Valkema R, Kwekkeboom DJ, et al.: Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21:111–129.PubMedCrossRefGoogle Scholar
  108. 108.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al.: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S–66S.PubMedGoogle Scholar
  109. 109.
    Plockinger U, Wiedenmann B: Biotherapy. Best Pract Res Clin Endocrinol Metab 2007;21:145–162.PubMedCrossRefGoogle Scholar
  110. 110.
    Guillermet-Guibert J, Lahlou H, Pyronnet S, et al.: Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535–551.PubMedCrossRefGoogle Scholar
  111. 111.
    Faiss S, Pape UF, Bohmig M, et al.: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689–2696.PubMedCrossRefGoogle Scholar
  112. 112.
    Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189.PubMedCrossRefGoogle Scholar
  113. 113.
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Volker Fendrich
    • 1
  • Peter Langer
    • 1
  • Detlef K. Bartsch
    • 1
  1. 1.Department of SurgeryUniversity Hospital Marburg and GiessenMarburgGermany

Personalised recommendations